Last edition
News about "Nxera Pharma "
Nxera Pharma and Shionogi Launch QUVIVIQ in Japan
QUVIVIQ™ is an oral Dual Orexin Receptor Antagonist (DORA) for the treatment of insomnia that selectively binds to receptors of the wake-promoting neuropeptide orexin (OX1R and OX2R), inhibiting excessive wakefulness and facilitating the transition to sleep.
Nxera Pharma | 19/12/2024 | By Aishwarya
Nxera Pharma to Get USD 35 Million from Neurocrine for Phase 2 Trial with NBI- '568
The NBI-’568-SCZ2028 dose-finding study met its primary endpoint for the once-daily 20 mg dose and was generally safe and well tolerated at all doses studied, supporting Neurocrine’s intentions to advance NBI- ‘568 into Phase 3 clinical trials in early 2025.
Nxera Pharma | 03/09/2024 | By Aishwarya
Nxera Pharma to Receive USD 4.6 Million from Centessa
Nxera Pharma has been expecting to receive USD 4.6 million in milestone payments from Centessa Pharmaceuticals under a license agreement regarding Nxera technology used to help design Centessa’s novel orexin receptor 2 (OX2R) agonist, ORX750.
Nxera Pharma | 30/05/2024 | By Aishwarya | 113
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy